The Use of Collagen IV for Noninvasive Assessment and Follow up of Liver Fibrosis After Successful DAA Treatment of HCV Infected Egyptians
Ali, A., Morssy, H., Abdelmageed, A., Abdelsamea, S., Ismail, H. (2024). The Use of Collagen IV for Noninvasive Assessment and Follow up of Liver Fibrosis After Successful DAA Treatment of HCV Infected Egyptians. EKB Journal Management System, 6(4), 453-470. doi: 10.21608/jmals.2024.307125.1026
Alaa S. Ali; Hesham A. Morssy; Asmaa M. Abdelmageed; Shaimaa M. Abdelsamea; Hisham Ismail. "The Use of Collagen IV for Noninvasive Assessment and Follow up of Liver Fibrosis After Successful DAA Treatment of HCV Infected Egyptians". EKB Journal Management System, 6, 4, 2024, 453-470. doi: 10.21608/jmals.2024.307125.1026
Ali, A., Morssy, H., Abdelmageed, A., Abdelsamea, S., Ismail, H. (2024). 'The Use of Collagen IV for Noninvasive Assessment and Follow up of Liver Fibrosis After Successful DAA Treatment of HCV Infected Egyptians', EKB Journal Management System, 6(4), pp. 453-470. doi: 10.21608/jmals.2024.307125.1026
Ali, A., Morssy, H., Abdelmageed, A., Abdelsamea, S., Ismail, H. The Use of Collagen IV for Noninvasive Assessment and Follow up of Liver Fibrosis After Successful DAA Treatment of HCV Infected Egyptians. EKB Journal Management System, 2024; 6(4): 453-470. doi: 10.21608/jmals.2024.307125.1026

The Use of Collagen IV for Noninvasive Assessment and Follow up of Liver Fibrosis After Successful DAA Treatment of HCV Infected Egyptians

Journal of Medical and Life Science
Article 1, Volume 6, Issue 4, December 2024, Page 453-470  XML PDF (1.3 MB)
Document Type: Original Article
DOI: 10.21608/jmals.2024.307125.1026
View on SCiNiTO View on SCiNiTO
Authors
Alaa S. Ali1; Hesham A. Morssy2; Asmaa M. Abdelmageed3; Shaimaa M. Abdelsamea4; Hisham Ismail email orcid 4
1Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt.
2Internal Medicine Department, Faculty of Medicine, Minia University, Minia 61519, Egypt
3Gastrointestinal Surgery Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
4Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt
Abstract
The use of noninvasive surrogate blood biomarkers for the assessment of liver fibrosis has gained increasing interest. In this study, 88 chronic hepatitis C patients (aged 21–68 years) were assessed for liver fibrosis using Collagen type IV (Col-IV), both before and one year after the end of successful DAA therapy for HCV infection. FibroScan was used to assess the degree of liver fibrosis. Using sandwich ELISA, the serum level (ng/mL) of Col-IV was determined. SPSS package was used to statistically examine the data. Before therapy, there was a strong association (r = 0.704; P < 0.0001) between the degree of fibrosis and the amount of Col IV. Furthermore, ROC curve analyses demonstrated that, when compared to a panel of routine indicators, Col-IV could distinguish individuals with significant fibrosis (F2-F4) and non-significant fibrosis (F0- F1) with a high degree of efficiency (95%). In 6% of treated patients, the degree of fibrosis regressed, remained unchanged in 75%, and progressed in 19%. It is noteworthy that patients experiencing regression of fibrosis had significantly lower mean levels of Col-IV (30.60 ± 4.23 vs. 22.40 ± 4.71; P < 0.001), while patients with stationary fibrosis did not significantly change (26.21 ± 1.81 vs. 26.68 ± 1.77; P > 0.05) and patients experiencing progression of fibrosis had significantly higher mean levels (32.35 ± 3.71 vs. 46.35 ± 3.09; P < 0.001). In conclusion, Col-IV has the potential to be a highly effective noninvasive marker for determining the extent of liver fibrosis both before and after the eradication of HCV infection.
Keywords
Liver Fibrosis; HCV; DAA; Biomarker; Collagen IV
Statistics
Article View: 173
PDF Download: 114